ArticleJournal of clinical and experimental hepatology
Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease.
Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global epidemiology of diabetes and prediabetes in lean or non-obese patients with NAFLD: a systematic review and meta-analysis.Annals of medicine · 2026Pooled it
- Cardioprotective Effects of 1,3 Butanediol in MASLD via Reversal of Cardiac Lipid Accumulation and Suppression of Cardiac Fibrosis.International journal of molecular sciences · 2026Article
- Prevalence of MASLD and fibrosis in Turkey: Results from a multicenter study of at-risk populations.PloS one · 2026Observational
- Gut microbial signatures associated with the Indian lean MASLD phenotype.Frontiers in nutrition · 2025Review
- The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what's different?Frontiers in endocrinology · 2025Review
- Complex Interaction Between Visceral Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of clinical and experimental hepatologyArticle
- Exploring diversity in Non-Alcoholic Fatty Liver Disease (NAFLD) among lean, overweight, and obese patients: A Multicenter study from India.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The current definition of lean is based on body mass index (BMI). However, BMI is an imperfect surrogate for adiposity and provides no information on central obesity (CO). Hence, we explored the differences in clinical profile and liver disease severity in lean patients with nonalcoholic fatty liver disease (NAFLD) with and without CO. Methods: One hundred seventy lean patients with NAFLD (BMI <23 kg/m Results: Of 170 patients with lean NAFLD, 96 (56.5%) had CO. Female gender (40.6% vs. 17.6%, Conclusion: Lean patients with NAFLD or MASLD and CO have more severe liver disease compared to those without CO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.